Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone palmitate dose response in schizophrenia
NCT00590577Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Mar 2007
- Primary completion
- Mar 2008
- Modality
- Metabolically Activated Prodrugs
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of paliperidone palmitate in schizophrenia (4 arms), sponsored by Johnson & Johnson. Primary endpoint: Change in Positive and Negative Syndrome Scale Total Score at 13 weeks. Started Mar 2007; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00590577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00590577.